Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2016—Siemens Healthcare Immulite 2000/2000 XPi TSI assay for the diagnosis of Graves’ disease is FDA cleared. The assay detects the presence of thyroid-stimulating antibodies only, is fully automated, and produces results in 65 minutes.
May 2016—BD mouse T-lymphocyte and B-lymphocyte kits, protocols, and software templates for the BD Accuri C6 flow cytometer aim to simplify the identification of mouse T and B lymphocytes, their subsets, and their activation markers. The kits include fluorescent antibodies, buffer systems, and controls needed for acquisition and analysis.
May 2016—Myriad Genetics announced an expanded companion diagnostics research collaboration with AbbVie to support the development of AbbVie’s investigational PARP inhibitor, veliparib.
May 2016—Leica Biosystems introduced the Aperio Versa, a combination digital pathology research scanner for bright-field, fluorescence, and FISH imaging. High levels of automation and an optional 200-slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.
May 2016—Abbott demonstrated a prototype of the company’s next-generation molecular diagnostics platform at a recent scientific event hosted for its customers. The new system is currently being designed from the ground up based on extensive input from laboratory customers.
May 2016—Great Basin Scientific has received FDA clearance for its Staph ID/R Blood Culture Panel. The panel is a sample-to-result, automated, DNA multiplex assay for simultaneous identification of Staphylococcus aureus and Staphylococcus species directly from positive blood cultures.
May 2016—The Sarstedt Group has acquired the laboratory automation business of m-u-t GmbH, headquartered in Wedel, Germany, and its direct customer business worldwide.
May 2016—Horizon Discovery Group has formed an immuno-oncology joint venture, Avvinity Therapeutics, with Centauri Therapeutics, a U.K.-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases.
May 2016—Fluxion Biosciences has launched two kits for enhanced circulating tumor cell isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system.
May 2016—With a grant from Innovate UK, Affymetrix will develop a health and economic benefits assessment for replacing surveillance cystoscopies with noninvasive genomic profiling from urinary cell-free DNA using the OncoScan FFPE Assay Kit.
